Entera Bio Ltd. (ENTX)
Stock Price:
$1.05 USD
-0.03 (-2.78%)
Updated Oct 28, 2020 1:00 PM EDT - Market open
Key Info
| Market Cap |
19.15M |
| Revenue (ttm) |
236,000 |
| Net Income (ttm) |
-10.80M |
| Shares Out |
18.23M |
| EPS (ttm) |
-0.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$1.05 |
| Previous Close |
$1.08 |
| Change ($) |
-0.03 |
| Change (%) |
-2.78% |
| Day's Open |
1.08 |
| Day's Range |
1.05 - 1.09 |
| Day's Volume |
18,566 |
| 52-Week Range |
1.00 - 3.40 |
More Stats
| Market Cap |
19.15M |
| Enterprise Value |
4.26M |
| Earnings Date (est) |
Apr 1, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
18.23M |
| Float |
10.63M |
| EPS (basic) |
0.89 |
| EPS (diluted) |
-0.82 |
| FCF / Share |
-0.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
70,292 |
| Short Ratio |
0.41 |
| Short % of Float |
0.66% |
| Beta |
1.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
81.13 |
| PB Ratio |
2.72 |
| Revenue |
236,000 |
| Operating Income |
-11.45M |
| Net Income |
-10.80M |
| Free Cash Flow |
-8.96M |
| Net Cash |
14.89M |
| Net Cash / Share |
0.82 |
| Gross Margin |
10.16% |
| Operating Margin |
-4,853.39% |
| Profit Margin |
-4,574.20% |
| FCF Margin |
-3,796.19% |
| ROA |
-77.73% |
| ROE |
-183.14% |
| ROIC |
1,592.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $1.05
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 0.24 | 0.50 | - | - |
| Revenue Growth | -52.8% | - | - | - |
| Gross Profit | 0.03 | 0.50 | - | - |
| Operating Income | -11.45 | -10.86 | -11.34 | -5.37 |
| Net Income | -10.80 | -10.30 | -11.20 | -1.20 |
| Shares Outstanding | 12.15 | 7.96 | 4.49 | 4.47 |
| Earnings Per Share | 0.89 | 1.31 | 2.49 | 0.78 |
| EPS Growth | -32.06% | -47.39% | 219.23% | - |
| Operating Cash Flow | -8.92 | -9.80 | -4.53 | -3.14 |
| Capital Expenditures | -0.04 | -0.07 | -0.05 | -0.04 |
| Free Cash Flow | -8.96 | -9.86 | -4.58 | -3.18 |
| Cash & Equivalents | 15.19 | 11.52 | 11.75 | 4.16 |
| Total Debt | 0.30 | - | 3.89 | 14.72 |
| Net Cash / Debt | 14.89 | 11.52 | 7.85 | -10.56 |
| Assets | 16.70 | 13.34 | 13.28 | 6.29 |
| Liabilities | 4.78 | 3.23 | 44.84 | 31.53 |
| Book Value | 11.92 | 10.12 | -31.56 | -25.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Entera Bio Ltd. |
| Country |
Israel |
| Employees |
19 |
| CEO |
Roger J. Garceau |
Stock Information
| Ticker Symbol |
ENTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ENTX |
| IPO Date |
June 28, 2018 |
Description
Entera Bio, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.